Cited by 22Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases

M‐Ras induces Ral and JNK activation to regulate MEK/ERK‐independent gene expression in MCF‐7 breast cancer cells

Open access
Castro, Ariel F., Campos, Tania, Babcock, Justin T., Armijo, Marisol E., Martínez‐Conde, Alfonso, Pincheira, Roxana, Quilliam, Lawrence A.·2012·Journal of Cellular Biochemistry

Abstract

Constitutive activation of M‐Ras has previously been reported to cause morphologic and growth transformation of murine cells, suggesting that M‐Ras plays a role in tumorigenesis. Cell transformation by M‐Ras correlated with weak activation of the Raf/MEK/ERK pathway, although contributions from other downstream effectors were suggested. Recent studies indicate that signaling events distinct from the Raf/MEK/ERK cascade are critical for human tumorigenesis. However, it is unknown what signaling events M‐Ras triggers in human cells. Using constitutively active M‐Ras (Q71L) containing additional mutations within its effector‐binding loop, we found that M‐Ras induces MEK/ERK‐dependent and ‐independent Elk1 activation as well as phosphatidylinositol 3 kinase (PI3K)/Akt and JNK/cJun activation in human MCF‐7 breast cancer cells. Among several human cell lines examined, M‐Ras‐induced MEK/ERK‐independent Elk1 activation was only detected in MCF‐7 cells, and correlated with Rlf/M‐Ras interaction and Ral/JNK activation. Supporting a role for M‐Ras signaling in breast cancer, EGF activated M‐Ras and promoted its interaction with endogenous Rlf. In addition, constitutive activation of M‐Ras induced estrogen‐independent growth of MCF‐7 cells that was dependent on PI3K/Akt, MEK/ERK, and JNK activation. Thus, our studies demonstrate that M‐Ras signaling activity differs between human cells, highlighting the importance of defining Ras protein signaling within each cell type, especially when designing treatments for Ras‐induced cancer. These findings also demonstrate that M‐Ras activity may be important for progression of EGFR‐dependent tumors. J. Cell. Biochem. 113: 1253–1264, 2012. © 2011 Wiley Periodicals, Inc.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcb.23458

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Castro, A. F., Campos, T., Babcock, J. T., Armijo, M. E., Martínez‐Conde, A., Pincheira, R., & Quilliam, L. A.
Affiliations
  • University of Concepción (CL)
  • Indiana University School of Medicine (US)
Corresponding author
Castro, Ariel F.
Venue
Journal of Cellular Biochemistry
Publisher
Wiley
Published
2012-02-23
Volume
113
Issue
4
Pages
1253-1264
ISSN
  • 0730-2312 (ISSN-L)
  • 1097-4644
OpenAlex
W2071034573
Cited by
22
References
60
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 1 · 2016: 2 · 2015: 1 · 2012: 3
FWCI
0.39
Type
journal article
Language
en
Open access
Locations
  • Journal of Cellular Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
Funders
  • University of California, San Francisco
  • National Cancer Institute (R01CA108647, CA108647)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords
M-Ras, Ral, JNK, Elk-1, PI3K/Akt signaling, RalF, EGFR, epidermal growth factor, estrogen-independent growth, breast cancer, MCF-7 cells
MeSH terms
Enzyme Activation, Female, Humans, Signal Transduction, Gene Expression Regulation, Enzymologic, Monomeric GTP-Binding Proteins, ral GTP-Binding Proteins, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Immunoprecipitation, MAP Kinase Kinase 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review